PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Xeris Biopharma’s glucagon injection becomes available in UK

Tetris Pharma’s Ogluo is the first ready-to-use, pre-mixed and pre-measured glucagon injection.

Tetris Pharma has launched Ogluo (glucagon injection) in the UK and this is now available by prescription for the treatment of severe hypoglycaemia in adults, adolescents and children aged two years and over with diabetes mellitus.

This was announced by Xeris BioPharma, who in July 2021 formed a licensing agreement with Tetris for the commercialisation of Ogluo (European brand name of Gvoke) in the EU, the UK and Switzerland (the Territory). Under the terms of this agreement, Xeris is responsible for product supply while Tetris is responsible for the commercialisation of Ogluo in the Territory, starting with the UK. Tetris aims for Ogluo to be launched in several countries across Europe during 2022.

Ogluo/Gvoke is the first prescription, ready-to-use, pre-mixed and pre-measured glucagon injection. It was approved by the US Food and Drug Administration (FDA) in September 2019 for use in the US and received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2020.

Hypoglycemia is a condition in which a patient’s blood sugar, or glucose level, is lower than normal. Signs of low blood sugar include trembling and tingling lips, and if untreated, one can experience blurred vision.

Paul Edick, chairman and CEO of Xeris, commented on the launch: “Just as Gvoke has the potential to change lives for people in the US with diabetes, we are delighted that Ogluo is now accessible to people in the UK and will be available in other European countries in 2022.”

Edick added: “Having a product that is ready-to-use will be a real benefit to both people with diabetes and their caregivers, in the case of a severe hypoglycemic event.”

Xeris is a biopharmaceutical company developing and commercialising therapies for patient populations in endocrinology, neurology, and gastroenterology. Gvoke is the company’s second commercially available product.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026